TheAIDSReader Members: Login | Register
The AIDS Reader SearchMedica Medline Drugs

Powered by SearchMedica

 
 

Home
 
NEWS
30 Years of HIV: Looking Back, Looking Ahead
http://www.medpagetoday.com - 5/20/13
Docs Don't Test Kids for STDs, HIV
http://www.medpagetoday.com - 5/6/13
PodMed: A Medical News Roundup from Johns Hopkins (with audio)
http://www.medpagetoday.com - 5/3/13
FDA Stalls Use of 2 HIV Drugs
http://www.medpagetoday.com - 4/29/13
Road to HIV Vaccine Hits Another Speed Bump
http://www.medpagetoday.com - 4/25/13
HIV Care Groups Fear Post-ACA Future
http://www.medpagetoday.com - 4/23/13
HAART Saves Heart in Kids with HIV (CME/CE)
http://www.medpagetoday.com - 4/22/13
Combo Defeats Fungal Meningitis in HIV (CME/CE)
http://www.medpagetoday.com - 4/3/13
HIV Infection Severity Linked to Afib (CME/CE)
http://www.medpagetoday.com - 4/3/13
Young Teens Not Having Sex (CME/CE)
http://www.medpagetoday.com - 4/1/13


 
RESOURCES

RELATED TOPICS

CancerNetwork: 
AIDS-Related Tumors


Consultant Live: 
HIV/AIDS

STDs

Infection

 


OTHER TRUSTED CLINICAL INFORMATION SOURCES


AIDS Education Global Information System (AEGIS)


AIDS Research Alliance


International Association of Physicians in AIDS Care


NIH Centers for Aids Research (CFAR)


Medline Plus: HIV/AIDS


NIH Treatment and Prevention Guidelines


UCSF HIV InSite NewsWatch

 


 

The AIDS Reader Online Archive »

 

 
INFORMATION FROM AIDS.gov BLOG
HIV Treatment Cascade Video Now Also Available in Spanish
AIDS.gov Blog - 5/23/13
“Ahora el video de la Cascada de Tratamiento de VIH también está disponible en español” Recently we shared an animated video about the HIV treatment cascade in the United States that has quickly become one of the most-watched videos ever on the AIDS.gov YouTube channel . We’re pleased to share the Spanish language version of this...
Digital Strategy: Delivering Better Results for the Public
AIDS.gov Blog - 5/23/13
Today marks one year since we released the Digital Government Strategy (PDF/ HTML5), as part of the President’s directive to build a 21st Century Government that delivers better services to the American people. The Strategy is built on the proposition that all Americans should be able to access information from their Government anywhere, anytime, and on any device; that open...
$1 Billion Health Care Innovation Awards Initiative Includes Opportunities for Models to Improve Care for PLWHA
AIDS.gov Blog - 5/22/13
Last week, U.S. Health and Human Services Secretary Kathleen Sebelius announced a nearly $1 billion initiative that will fund grant awards and evaluation to build on the Obama administration’s work to transform the health care system by delivering better care and lowering costs for taxpayers and patients. The Health Care Innovation Awards are funded by...
Hanging out with “We the Geeks”
AIDS.gov Blog - 5/21/13
Editor’s note: At AIDS.gov, we continue to look for ways to increase the reach of existing HIV/AIDS programs through technology and innovation. The White House is leading a Google+ hangout series about that very topic. Read more from the Office of Science and Technology Policy. This live event has concluded. Watch the first “We the Geeks”...
HIV Vaccine Research Update and HVTN 505
AIDS.gov Blog - 5/21/13
May 18th was HIV Vaccine Awareness Day, and we wanted to remind you of several posts we did last week on that subject. On Friday, we featured a guest post, Moving Forward on HIV Vaccine Awareness Day, by Dr. Nelson Michael, director of the U.S. Military HIV Research Program. And then we posted this video...
More Results
 
FEATURED NEWS

cervical cancerConsidering everything else to there is to deal with when treating a HIV-positive woman, it might be all too easy to let one simple priority slide: the Pap smear. 
 

The first multicohort prospective study of HIV and cervical cancer offers sobering cause to reorient priorities. HIV-infected women have a higher incidence of precancerous cervical lesions.

The risk increases significantly as CD4 counts decrease.


HIV-infected Women Have Higher Risk of Incident Invasive Cervical Cancer
 

 
LATEST ARTICLES

The AIDS Reader. Vol. 18 No. 12
Images in HIV/AIDS Liron Pantanowitz, MD; Bruce J. Dezube, MD—Series Editors 

HIV and Viral Hepatitis Coinfection

By

Heike Varnholt, MD; Bruce J. Dezube, MD; Liron Pantanowitz, MD
AIDS Reader. 2008;18:613-614]
| December 1, 2008


Dr Varnholt is assistant professor in the department of pathology at the University of North Carolina, Chapel Hill. Dr Dezube is associate professor of medicine in the department of medicine (hematology-oncology division) at Beth Israel Deaconess Medical Center, Harvard Medical School, Boston. Dr Pantanowitz is assistant professor of pathology in the department of pathology at Baystate Medical Center, Tufts University School of Medicine, Springfield, Mass. Drs Dezube and Pantanowitz are the editors of this column.


A 44-year-old man with known HIV infection for more than 20 years presented with fatigue, nausea, and vomiting with a recent weight loss of 40 lb. His most recent CD4+ cell count was 206/µL, and his HIV RNA level was below 50 copies/mL. However, because of prior intolerance, the patient was no longer taking his antiretroviral medication. He was coinfected with hepatitis B virus (HBV) (serum hepatitis B surface antigen [HBsAg]-positive; unknown E antigen status) and hepatitis C virus (HCV) (HCV RNA level greater than 1,000,000 copies/mL; genotype not available).

The patient reported prior abuse of injection drugs, alcohol(Drug information on alcohol), and tobacco. He was not jaundiced nor did he have stigmata of chronic liver disease. No ascites or palpable masses were found on abdominal examination. His serum transaminase levels were mildly increased (alanine aminotransferase, 99 U/L [normal, 0 to 41]; aspartate aminotransferase 12 U/L [normal, 0 to 38]). The remaining laboratory test results were unremarkable for total bilirubin (0.3 mg/dL), serum albumin (3.9 g/dL), coagulation profile, and α-fetoprotein (3.8 ng/mL).

Figure 1. A liver core needle biopsy specimen showing moderate portal and periportal inflammation with focal lobular necroinflammatory activity (grade 2 hepatitis) (hematoxylin-eosin stain, original magnification x400).

A liver biopsy sample was taken for staging of his liver disease and showed signs of chronic hepatitis. There was portal and periportal chronic inflammation with interface hepatitis and concomitant focal necroinflammatory activity within liver lobules (Figure 1). This was consistent with grade 2 inflammation. In addition, there was a moderate amount of fibrosis with portal-portal bridging, ie, stage 2 fibrosis (using the Batts and Ludwig system). There were many prominent so-called ground-glass hepatocytes (Figure 2) seen throughout the liver core needle biopsy specimen. Ground-glass hepatocytes represent a histological hallmark of the accumulation of proteins in the endoplasmic reticulum and may be seen in chronic hepatitis B, wherein the proteins are surface antigen. Indeed, an immunohistochemical stain for HBsAg in this case showed strong cytoplasmic and membranous immunoreactivity within the liver parenchyma (Figure 3), confirming HBV infection of hepatocytes.

Figure 2. Ground-glass hepatocytes (arrows) with an eosinophilic-translucent cytoplasm in this liver core needle biopsy specimen are indicative of hepatitis B virus infection (hematoxylin-eosin stain, original magnification ×600).

Chronic liver disease caused by concomitant infection with HBV, HCV, or both, complicates the management of and prognosis for persons with HIV/AIDS and may lead to cirrhosis, end-stage liver disease, and hepatocellular carcinoma.1-3 The high rates of hepatitis B and C (10% and 25%, respectively) in HIV-infected persons are caused by shared risk factors and similar modes of infection among these 3 viruses. These blood-borne pathogens can all be transmitted via sexual contact, by injection drug use, or from mother to child during or after childbirth.

Viral hepatitis–related liver disease is a major cause of morbidity and mortality in persons with HIV/AIDS. Coinfected persons have higher HCV viral loads; more rapid progression of liver disease to cirrhosis, end-stage liver disease, and hepatocellular carcinoma; greater risk of anemia and leukopenia; and more rapid progression to AIDS and ultimately death.4 Furthermore, coinfection complicates antiretroviral treatment by increasing the risk of drug-drug interactions and drug-related hepatotoxicity.5 HCV infection also increases the risk of Waldenström macroglobulinemia and non-Hodgkin lymphoma.6

Figure 3. Cytoplasmic immunoreactivity (brown staining) of hepatocytes with hepatitis B surface antigen antibody confirms chronic infection with hepatitis B virus (original magnification ×400).

Screening of all HIV-infected persons for hepatitis B and C has been recommended in guidelines developed in Europe and the United States.7 Furthermore, all injection drug users should be screened for hepatitis B and C regardless of their HIV status. HIV-negative men who have sex with men need not be screened for hepatitis because of the low risk of infection via sexual transmission. Early vaccination against hepatitis B and A is recommended for persons with and at risk for HIV infection because of the poor immunogenicity of hepatitis B and A vaccines in advanced HIV infection. Because treated HIV-infected persons benefit from improved control of HIV replication and live longer, their risk of dying of cancer is increased.3 In particular, as alluded to before, hepatocellular carcinoma has been shown to develop sooner in HIV/HCV-coinfected patients than in HCV-monoinfected persons.2 In patients with hepatocellular carcinoma who are not being treated for their HIV infection, an undetectable HIV RNA level is associated with significantly better survival.2

The need to treat viral hepatitis in HIV-positive persons is based on several factors, such as hepatitis viremia, extent of biochemical abnormalities, and severity of liver disease, and should take into account the ability of the patient to adhere to a medical regimen. Persons coinfected with HIV and HBV and/or HCV should be monitored closely for progression of their liver disease as well as the development of hepatocellular carcinoma. Current recommendations related to screening for hepatocellular carcinoma in this population warrants clarification.8

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.





References
1. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol. 2008;48:353-367.
2. Bräu N, Fox RK, Xiao P, et al; North American Liver Cancer in HIV Study Group. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol. 2007;47:527-537.
3. Pantanowitz L, Schlecht HP, Dezube BJ. The growing problem of non-AIDS-defining malignancies in HIV. Curr Opin Oncol. 2006;18:469-478.
4. Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat. 2007;14:371-386.
5. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.
6. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297:2010-2017.
7. Rockstroh JK, Bhagani S, Benhamou Y, et al; EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 2008;9:82-88.
8. Bower M, Collins S, Cottrill C, et al; AIDS Malignancy Subcommittee. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med. 2008;9:336-388.

 
IMAGES IN AIDS/HIV

Parotid Gland Deformities in HIV Seropositive Patients: The Best Choice for Cosmetic Control
April 9, 2012

More than half of people with HIV infection in the United States develop head and neck lesions. Common among these is enlargement of the parotid gland, which causes disfigurement and therefore distress. This review discusses the evidence for radiation treatment as the best option, as well as the dangers of choosing the wrong treatment for this benign comorbidity of HIV-positive status.

HIV-Positive Male Presents With Multiple Symptoms and Has a History of Colonic Polyps
December 19, 2011

A 20-year-old HIV positive male presents with headache, nausea, and vomiting following a seizure. History is notable for 3 surgeries to remove colonic polyps. Subsequent MRI brain scan with contrast reveals a mass in the left frontal lobe which is removed. The image above is an H&E stained section of the mass.

Severe Psoriasis in Advanced HIV Infection
February 3, 2010

A 50-year-old African American man with HIV infection had a CD4+ T-cell count of 18/μL (1%), CD8+ cell count of 1035/μL (69%), and CD4:CD8 ratio of 0.01 at the time of diagnosis. He had multiple erythematosquamous skin lesions over his forehead, face, chest, back, and extremities

Keloid After Herpes Zoster in an HIV-Infected Person
May 11, 2009

Herpes zoster, or shingles, is characterized by unilateral radicular pain and a vesicular rash that is generally limited to a single dermatome. It results from reactivation of latent varicella-zoster virus (VZV) within the sensory ganglia.

 
MEDLINE
Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts.
pubmed.gov - 2/28/13
The introduction of HAART (highly-active-antiretroviral-therapy) has resulted in extended survival of HIV positive patients. Conversely, due to the prolonged expectancy of life and the ageing of the HIV positive population, tumors are now one of the major cause of death, and among them hepatocellular carcinoma (HCC) has become a growing concern in these patients. Considering the potential anti-tumoral effects of HIV protease inhibitors, we decided to evaluate the anti-tumoral activity of Amprenavir on liver carcinoma and to evaluate its potential synergistic effects in combination with standard chemoterapic drugs, such as Doxorubicin. Our results indicate that Amprenavir had direct inhibitory effects on invasion of Huh-7 hepatocarcinoma cell lines, inhibiting MMP proteolytic activation. Amprenavir was able to delay the growth of hepatocarcinoma xenografts in nude mice and had a synergistic effect with Doxorubicin. Furthermore, Amprenavir was able to promote regression of
Standard-dose vs high-dose multivitamin supplements for HIV.
pubmed.gov - 2/12/13
23403670 2013 02 13 2013 02 19 1538-3598 309 6 Feb 13 JAMA 545-6 10.1001/jama.2012.216991 Padayatty Sebastian J SJ Levine Mark M eng Comment Letter United States JAMA 7501160 0098-7484 0 Vitamins 12001-76-2 Vitamin B Complex 1406-18-4 Vitamin E 50-81
Standard-dose vs high-dose multivitamin supplements for HIV--reply.
pubmed.gov - 2/12/13
23403671 2013 02 13 2013 02 19 1538-3598 309 6 Feb 13 JAMA 546 10.1001/jama.2012.216995 Isanaka Sheila S Mugusi Ferdinand F Fawzi Wafaie W WW eng Comment Letter United States JAMA 7501160 0098-7484 0 Vitamins 12001-76-2 Vitamin B Complex 1406-18-4
More Results


 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Elephantiasis Nostras Verrucosa Secondary to Kaposi Sarcoma: A Rare Case
  • Fatal Herpes Simplex Virus Type 2 Pneumonia in a Person With AIDS
  • Extensive Development of Flat Warts as a Cutaneous Manifestation of Immune Reconstitution Syndrome
  • Neuropsychiatric Aspects of Coinfection With HIV and Hepatitis C Virus
  • Sweet Syndrome and Syphilis in an HIV-Infected Person
  • Parotid Gland Deformities in HIV Seropositive Patients: The Best Choice for Cosmetic Control
  • HIV-Associated Nemaline Rod Myopathy: Role of Intravenous Immunoglobulin Therapy in Two Persons With HIV/AIDS
  • HIV Physician Shortage? Bring On the Nurses!
  • Editorial Comment: Tenofovir Nephrotoxicity—The Disconnect Between Clinical Trials and Real-World Practice
  • HIV Physician Shortage? Bring On the Nurses!
  • New Recommendations for Qualifications to Treat HIV Infection
  • Polypharmacy in People with HIV: A Growing Problem
  • Healthcare Reform: The Implications for People with HIV
  • Pre-Exposure Prophylaxis (PrEP): Is It Cost-Effective?
Click here to subscribe to our newsletter


 
PRACTICE GUIDELINES
National Guideline Clearinghouse | Cognitive disorders and HIV/AIDS: HIV-associated dementia and delirium.
www.guidelines.gov -
National Guideline Clearinghouse | Trauma and post-traumatic stress disorder in patients with HIV/AIDS.
www.guidelines.gov -
National Guideline Clearinghouse | Suicidality and violence in patients with HIV/AIDS.
www.guidelines.gov -
National Guideline Clearinghouse | Evidence-based guideline: antiepileptic drug selection for people with HIV/AIDS. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic
www.guidelines.gov -
National Guideline Clearinghouse | Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel.
www.guidelines.gov -
National Guideline Clearinghouse | Depression and mania in patients with HIV/AIDS.
www.guidelines.gov -
National Guideline Clearinghouse | HIV/AIDS evidence-based nutrition practice guideline.
www.guidelines.gov -
National Guideline Clearinghouse | Adapting your practice: treatment and recommendations for homeless patients with HIV/AIDS.
www.guidelines.gov -
National Guideline Clearinghouse | Diagnosis of pediatric HIV infection in HIV-exposed infants.
www.guidelines.gov -
ACP Adult Immunization Initiative
www.acponline.org -
More Results


 
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access
Judy Capko,  May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins,  May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD,  May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.
Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz,  May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD,  May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
 

 

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy